Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Pregabalin is a novel compound that has been shown to have efficacy in the treatment of generalised anxiety disorder and is licensed for the treatment of the disorder in the European Union. Aims: The current study was designed to evaluate the safety and efficacy of pregabalin, an α 2 δ-ligand, in the treatment of generalised anxiety disorder in people 65 years and older. Method: This was a double-blind, randomised (2:1), placebo-controlled, 8-week trial of pregabalin, in flexible doses of 150–600 mg/day, in the treatment of DSM–IV generalised anxiety disorder with a baseline Hamilton Rating Scale for Anxiety (HRSA) total score ⩾20. The primary outcome was end-point (week 8 or last visit, with last observation carried forward (LOCF)) change in HRSA total score. Results: A total of 273 patients (women, 78%; mean age, 72 years (s.d.=6); mean baseline HRSA total score, 26 (s.d.=4.6)) were randomised and received study treatment. On the primary intent-to-treat LOCF analysis, pregabalin was associated with a 2-point greater reduction in HRSA total score than placebo (12.87 v. 10.7; P <0.05). In a post hoc repeated measures mixed-effect model analysis, pregabalin was associated with significantly greater improvement than placebo in the HRSA total score from week 2 (–9.8 (s.d.=0.6) v. −7.2 (s.d.=0.8); P =0.0052) through week 8 (–14.4 (s.d.=0.6) v. −11.6 (s.d.=0.8); P =0.0070). Significant improvement was observed in the pregabalin group on both the HRSA psychic and somatic anxiety factors. There was a significantly greater decrease from baseline in mean Hamilton Rating Scale for Depression (HRSD) score with pregabalin compared with placebo (–5.48 (s.d.=0.46) v. −4.02 (s.d.=0.59); P =0.041). Pregabalin was well-tolerated, with almost all adverse events in the mild-to-moderate range, and self-limiting (median duration of 4–16 days). Discontinuations due to adverse events were similar for pregabalin (10.7%) and placebo (9.4%). Conclusions: Pregabalin, in doses of 150–600 mg/day, was a safe and effective treatment of generalised anxiety disorder in patients 65 years and older. The anxiolytic efficacy of pregabalin had an early onset (by 2 weeks) and significantly improved both psychic and somatic symptoms of anxiety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
Bruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
Anxiety and Depression in Later Life: Co-Occurrence and Communality of Risk Factors
Beekman, A. T. F., de Beurs, E., van Balkom, A. J. L. M., Deeg, D. J. H., van Dyck, R., & van Tilburg, W. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.89 · Cited by 669
de BEURS, E., BEEKMAN, A. T. F., van BALKOM, A. J. L. M., DEEG, D. J. H., van DYCK, R., & van TILBURG, W. (1999) · Psychological Medicine · doi:10.1017/s0033291799008351 · Cited by 378
Safety of benzodiazepines in the geriatric population
Madhusoodanan, S., & Bogunovic, O. J. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.485 · Cited by 195
Bech, P., Allerup, P., Maier, W., Albus, M., Lavori, P., & Ayuso, J. L. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.2.206 · Cited by 75
Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam
Beekman (1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1099-1166(1998100)13:10 · Cited by 2
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“compared with placebo [1354].”
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
A lifespan view of anxiety disorders
Lenze, E. J., & Wetherell, J. L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/elenze · Cited by 227
Interventions for generalized anxiety disorder in older adults: Systematic review and meta-analysis
Gonçalves, D. C., & Byrne, G. J. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.08.010 · Cited by 227
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02966.x · Cited by 216
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“been evaluated in older adults with GAD and found to be efficacious and well-tolerated both as monotherapy [84] and as an adjunctive intervention in antidepressant-resistant GAD [85].”
MethodPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments
Andreescu, C., & Varon, D. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0595-8 · Cited by 85
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Oladapo, A. O., Barner, J. C., Rascati, K. L., & Strassels, S. A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.007 · Cited by 24
Metadata
- Authors
- Montgomery, S., Chatamra, K., Pauer, L., Whalen, E., & Baldinetti, F.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2008-11
- Volume
- 193
- Issue
- 5
- Pages
- 389-394
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2115663250
- Cited by
- 131
- References
- 7
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.